Algert Global LLC Cuts Stock Position in LivaNova PLC $LIVN

Algert Global LLC lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 47.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 160,934 shares of the company’s stock after selling 145,265 shares during the quarter. Algert Global LLC owned about 0.29% of LivaNova worth $8,430,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in LIVN. State of Wyoming purchased a new stake in LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC boosted its position in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. UMB Bank n.a. boosted its position in LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after buying an additional 306 shares during the period. Bayforest Capital Ltd grew its stake in shares of LivaNova by 44.8% in the third quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock worth $48,000 after acquiring an additional 284 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of LivaNova by 90.8% in the third quarter. GAMMA Investing LLC now owns 1,202 shares of the company’s stock worth $63,000 after acquiring an additional 572 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on LIVN shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $66.00 price objective on shares of LivaNova in a research note on Friday, January 9th. Barclays boosted their target price on LivaNova from $67.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. KeyCorp initiated coverage on LivaNova in a report on Friday, December 19th. They set an “overweight” rating and a $81.00 price target on the stock. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Finally, Robert W. Baird set a $75.00 price objective on LivaNova in a research note on Tuesday, December 16th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $74.78.

LivaNova Price Performance

Shares of LIVN opened at $61.43 on Tuesday. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $71.92. The firm’s fifty day simple moving average is $64.96 and its 200-day simple moving average is $59.82. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of -13.77 and a beta of 0.92. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.06. The business had revenue of $360.86 million during the quarter, compared to analysts’ expectations of $354.31 million. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities analysts forecast that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.